Search

Objective: the aim of this study is to investigate the in vitro antioxidant activity, the total phenol and flavonoid content and the possible protective effects of commercial propolis on gentamicin-induced nephrotoxicity in rabbits. Methods: the in vitro antioxidant activity was measured by ferric reducing antioxidant power assay and cupric reducing antioxidant capacity assay, the total phenols content was measured by folin–ciocalteau assay, the flavonoids content by the alcl3 colorimetric method and the renoprotective effects of propolis methanol extract was evaluated in a rabbit model of gentamicin-induced nephrotoxicity. The protective effects of propolis on gentamicin-induced nephrotoxicity in rabbits were evaluated through biochemical parameter (measuring serum urea and creatinine) and histopathological alterations in kidneys Results: methanol extract of propolis showed a strong antioxidant activity, which is attributed to its high phenolic and flavonoid contents. Oral administration of propolis extract to rabbits at a dose of 1 mg/kg body weight significantly protected against histopathological and biochemical alterations induced by gentamicin. Conclusion: the present study demonstrated that commercial propolis is strong antioxidant and is effective for the prevention of gentamicin-induced renal damage in rabbits

At a time when human African trypanosomiasis (HAT) elimination again seems a reachable goal in many parts of sub-Saharan Africa, it is becoming increasingly important to characterise the factors involved in disease resurgence or maintenance to develop sustainable control strategies. In this study conducted in the Forecariah mangrove focus in Guinea, HAT patients and serological suspects (SERO) were identified through mass screening of the population with the Card Agglutination Test for Trypanosomiasis (CATT) and were followed up for up to 2 years. Analysis of the samples collected during the follow-up of HAT patients and SERO was performed with PCR (TBR1/TBR2) and the trypanolysis serological test (TL) in order to clarify the role played by these individuals in the epidemiology of HAT. PCR positivity was higher in TL + than in SERO TL − (50% vs. 18%, respectively). Whereas CATT plasma titres decreased both in treated HAT patients and SERO TL − , SERO TL + maintained high CATT titres. Four out of 17 SERO TL + developed HAT during the study. These results strongly suggest that SERO TL + individuals are asymptomatic carriers. In the context where disease prevalence is sufficiently low, treating SERO TL + individual may thus be of crucial importance in order to cut transmission.

Treatment of second-stage gambiense human African trypanosomiasis relied on toxic arsenic-based derivatives for over 50 years. The availability and subsequent use of eflornithine, initially in monotherapy and more recently in combination with nifurtimox (NECT), has drastically improved the prognosis of treated patients. However, NECT logistic and nursing requirements remain obstacles to its deployment and use in peripheral health structures in rural sub-Saharan Africa. Two oral compounds, fexinidazole and SCYX-7158, are currently in clinical development. The main scope of this article is to discuss the potential impact of new oral therapies to improve diagnosis-treatment algorithms and patients' access to treatment, and to contribute to reach the objectives of the recently launched gambiense human African trypanosomiasis elimination program.

Kinetic models of metabolism require detailed knowledge of kinetic parameters. However, due to measurement errors or lack of data this knowledge is often uncertain. The model of glycolysis in the parasitic protozoan Trypanosoma brucei is a particularly well analysed example of a quantitative metabolic model, but so far it has been studied with a fixed set of parameters only. Here we evaluate the effect of parameter uncertainty. In order to define probability distributions for each parameter, information about the experimental sources and confidence intervals for all parameters were collected. We created a wiki-based website dedicated to the detailed documentation of this information: the SilicoTryp wiki (http://silicotryp.ibls.gla.ac.uk/wiki/Glycolysis). Using information collected in the wiki, we then assigned probability distributions to all parameters of the model. This allowed us to sample sets of alternative models, accurately representing our degree of uncertainty. Some properties of the model, such as the repartition of the glycolytic flux between the glycerol and pyruvate producing branches, are robust to these uncertainties. However, our analysis also allowed us to identify fragilities of the model leading to the accumulation of 3-phosphoglycerate and/or pyruvate. The analysis of the control coefficients revealed the importance of taking into account the uncertainties about the parameters, as the ranking of the reactions can be greatly affected. This work will now form the basis for a comprehensive Bayesian analysis and extension of the model considering alternative topologies., Author Summary An increasing number of mathematical models are being built and analysed in order to obtain a better understanding of specific biological systems. These quantitative models contain parameters that need to be measured or estimated. Because of experimental errors or lack of data, our knowledge about these parameters is uncertain. Our work explores the effect of including these uncertainties in model analysis. Therefore, we studied a particularly well curated model of the energy metabolism of the parasite Trypanosoma brucei, responsible for African sleeping sickness. We first collected all the information we could find about how the model parameters were defined on a website, the SilicoTryp wiki (http:///silicotryp.ibls.gla.ac.uk/wiki/). From this information, we were able to quantify our uncertainty about each parameter, thus allowing us to analyse the model while explicitly taking these uncertainties into account. We found that, even though the model was well-defined and most of its parameters were experimentally measured, taking into account the remaining uncertainty allows us to gain more insight into model behavior. We were able to identify previously unrecognised fragilities of the model, leading to new hypotheses amenable to experimental testing.

Background Active case detection through mass community screening is a major control strategy against human African trypanosomiasis (HAT, sleeping sickness) caused by T. brucei gambiense. However, its impact can be limited by incomplete attendance at screening sessions (screening coverage) and diagnostic inaccuracy. Methods We developed a model-based approach to estimate the true prevalence and the fraction of cases detected during mass screening, based on observed prevalence, and adjusting for incomplete screening coverage and inaccuracy of diagnostic algorithms for screening, confirmation and HAT stage classification. We applied the model to data from three Médecins Sans Frontières projects in Uganda (Adjumani, Arua-Yumbe) and Southern Sudan (Kiri). Results We analysed 604 screening sessions, targeting about 710 000 people. Cases were about twice as likely to attend screening as non-cases, with no apparent difference by stage. Past incidence, population size and repeat screening rounds were strongly associated with observed prevalence. The estimated true prevalence was 0.46% to 0.90% in Kiri depending on the analysis approach, compared to an observed prevalence of 0.45%; 0.59% to 0.87% in Adjumani, compared to 0.92%; and 0.18% to 0.24% in Arua-Yumbe, compared to 0.21%. The true ratio of stage 1 to stage 2 cases was around two-three times higher than that observed, due to stage misclassification. The estimated detected fraction was between 42.2% and 84.0% in Kiri, 52.5% to 79.9% in Adjumani and 59.3% to 88.0% in Arua-Yumbe. Conclusions In these well-resourced projects, a moderate to high fraction of cases appeared to be detected through mass screening. True prevalence differed little from observed prevalence for monitoring purposes. We discuss some limitations to our model that illustrate several difficulties of estimating the unseen burden of neglected tropical diseases.

Background In a mammalian host, the cell surface of African trypanosomes is protected by a monolayer of a single variant surface glycoprotein (VSG). The VSG is central to antigenic variation; one VSG gene is expressed at any one time and there is a low frequency stochastic switch to expression of a different VSG gene. The genome of Trypanosoma brucei contains a repertoire of > 1000 VSG sequences. The degree of conservation of the genomic VSG repertoire in different strains has not been investigated in detail. Results Eighteen expressed VSGs from Ugandan isolates were compared with homologues (> 40 % sequence identity) in the two available T. brucei genome sequences. Fourteen homologues were present in the genome of Trypanosoma brucei brucei TREU927 from Kenya and fourteen in the genome of T. b. gambiense Dal972 from Cote d'Ivoire. The Ugandan VSGs averaged 71% and 73 % identity to homologues in T. b. brucei and T. b. gambiense respectively. The sequence divergence between homologous VSGs from the three different strains was not random but was more prevalent in the parts of the VSG believed to interact with the host immune system on the living trypanosome. Conclusion It is probable that the VSG repertoires in the different isolates contain many common VSG genes. The location of divergence between VSGs is consistent with selection for strain-specific VSG repertoires, possibly to allow superinfection of an animal by a second strain. A consequence of strain-specific VSG repertoires is that any vaccine based on large numbers of VSGs from a single strain will only provide partial protection against other strains.

International audience; The pharmacokinetics of megazol (2-amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazol, CAS 19622-55-0) was investigated after a 100 mg/kg oral administration to six primates infected with Trypanosoma brucei gambiense. The plasma levels of megazol were between 0.2 mu g/ml and 46 mu g/ml 24 h after dosing in all animals. In animals with prolonged infection, megazol absorption was accelerated (T-max was 4 h compared with 8 h, for day 53 and day 39 post inoculation) but the amount absorbed was not modified. The megazol concentrations in the cerebrospinal fluid represented between 5.5 % and 10.6 %, of the plasma levels at the same rimes. Unchanged megazol was eliminated predominantly via the kidneys: 46-96 % of the ingested dose was recovered in the urine, compared with 0-5 % in the faeces. Furthermore, this urinary elimination of megazol was altered in animals with prolonged infections. In the urine, 4 unknown metabolites were observed, unchanged megazol was characterized by LC-MS/MS. This study indicates that megazol crosses the blood-brain barrier after oral administration. Prolonged infections affect the absorption of megazol and its urinary elimination.